Literature DB >> 16767878

[Diarrhea and vaccines: current developments].

P Landry1.   

Abstract

Diarrhoea is a main concern for travellers, populations of developing countries and children. Causative pathogens are numerous. An efficient vaccine against cholera is available, also offering a 50% cross-protection against E. Coli enterotoxin (ETEC), however its efficacy is only 23% against all-causes traveller's diarrhoea. Rotavirus can be responsible for severe diarrhoea in infants but rarely causes traveller's diarrhoea. Two new vaccines being under development appear effective and well-tolerated but too expensive for developing countries which most need them. To date, the live oral Ty21a vaccine remains frequently prescribed in Switzerland, with limited indications and suboptimal efficacy. A new oral vaccine is under development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16767878

Source DB:  PubMed          Journal:  Rev Med Suisse        ISSN: 1660-9379


  2 in total

1.  Vaccination strategies to combat an infectious globe: oral cholera vaccines.

Authors:  Rosa M López-Gigosos; Elena Plaza; Rosa M Díez-Díaz; Maria J Calvo
Journal:  J Glob Infect Dis       Date:  2011-01

2.  Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea.

Authors:  Rosa López-Gigosos; Pedro Garcia-Fortea; Maria J Calvo; Emilia Reina; Rosa Diez-Diaz; Elena Plaza
Journal:  BMC Infect Dis       Date:  2009-05-16       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.